What Is 22q11 deletion

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 15, 2026

Quick Answer: 22q11.2 deletion syndrome is a genetic disorder caused by a microdeletion on chromosome 22 at position q11.2, affecting approximately 1 in 4,000 live births. It leads to a wide range of developmental, cardiac, and immune issues due to the loss of about 30 to 40 genes in the deleted region.

Key Facts

Affects about 1 in 4,000 newborns worldwide
Caused by a deletion at chromosome 22q11.2 location
Over 180 clinical features associated with the syndrome
85% of cases occur spontaneously, not inherited
Diagnosed via FISH or chromosomal microarray testing

Overview

22q11.2 deletion syndrome, also known as DiGeorge syndrome or velocardiofacial syndrome, is one of the most common human chromosomal deletion disorders. It results from a missing segment of DNA on the long arm of chromosome 22, specifically at position q11.2, which disrupts normal embryonic development.

This condition affects multiple body systems and can lead to highly variable symptoms among individuals. Early diagnosis and multidisciplinary care are crucial for improving long-term outcomes and quality of life.

Chromosome 22: The deletion occurs on the long arm (q) at position 11.2, removing a segment of about 3 million base pairs containing 30 to 40 genes.
Incidence rate: It affects approximately 1 in 4,000 live births, making it more common than cystic fibrosis or Down syndrome in some populations.
Common name origins: The syndrome is also called DiGeorge syndrome after Dr. Angelo DiGeorge, who first described the parathyroid and thymus deficiencies in the 1960s.
Variability: Over 180 clinical features have been associated with 22q11.2DS, including heart defects, cleft palate, and learning difficulties.
Diagnosis: Most cases are confirmed using fluorescence in situ hybridization (FISH) or chromosomal microarray analysis, which can detect the microdeletion.

How It Works

The 22q11.2 deletion disrupts the normal function of several critical genes involved in early development, particularly those affecting the third and fourth pharyngeal pouches during fetal growth. This leads to structural and functional abnormalities in the heart, face, immune system, and endocrine organs.

Gene TBX1: This gene is considered a major contributor; mutations or deletions in TBX1 are linked to heart defects and facial anomalies seen in the syndrome.
Thymic hypoplasia: Underdevelopment of the thymus gland leads to T-cell deficiency, increasing susceptibility to infections and autoimmune disorders.
Parathyroid issues: The deletion often causes hypoparathyroidism, resulting in low calcium levels (hypocalcemia) that can trigger seizures in newborns.
Cardiac defects: About 75% of patients have congenital heart defects, such as tetralogy of Fallot or interrupted aortic arch.
Neuropsychiatric risks: Individuals face a 25–30% risk of schizophrenia in adulthood, one of the highest known genetic associations with psychosis.
Inheritance pattern: Though most cases (85%) arise de novo, it follows an autosomal dominant pattern when inherited from a parent.

Comparison at a Glance

Below is a comparison of 22q11.2 deletion syndrome with other common genetic conditions based on prevalence, genetic cause, and key features.

Condition	Genetic Cause	Prevalence	Key Features	Inheritance Pattern
22q11.2 Deletion Syndrome	Microdeletion at 22q11.2	1 in 4,000	Heart defects, immune deficiency, cleft palate	Autosomal dominant (mostly de novo)
Down Syndrome	Trisomy 21	1 in 700	Intellectual disability, distinct facial features	Chromosomal nondisjunction
Cystic Fibrosis	CFTR gene mutation	1 in 3,500	Lung disease, pancreatic insufficiency	Autosomal recessive
Williams Syndrome	7q11.23 deletion	1 in 7,500	Cardiovascular disease, hypersociability	Autosomal dominant
Prader-Willi Syndrome	15q11-13 deletion (paternal)	1 in 10,000–30,000	Obesity, hypotonia, hyperphagia	Imprinted gene deletion

This comparison highlights how 22q11.2 deletion syndrome stands out due to its multisystem involvement and high rate of spontaneous mutations. Unlike recessive disorders, its dominant nature means a single copy of the deletion is sufficient to cause the condition, though expressivity varies widely.

Why It Matters

Understanding 22q11.2 deletion syndrome is critical for early intervention and long-term management. Because symptoms span multiple medical specialties, coordinated care improves outcomes significantly.

Early screening: Newborns with heart defects or cleft palate should be tested for 22q11.2 deletion to enable timely treatment.
Immunological monitoring: Regular immune function tests help manage T-cell deficiencies and prevent life-threatening infections.
Calcium management: Neonatal hypocalcemia requires immediate supplementation to prevent seizures and neurological damage.
Educational support: Up to 70% of children have learning disabilities, necessitating individualized education plans.
Mental health: Regular psychiatric evaluations are recommended due to high risks of ADHD, anxiety, and schizophrenia.
Family counseling: Genetic counseling helps families understand recurrence risks, especially since 10–15% of cases are inherited.

With advances in genetic testing and growing awareness, more individuals are being diagnosed earlier, leading to better health outcomes. Multidisciplinary clinics specializing in 22q11.2DS are now established in many countries, improving access to integrated care.